These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 28378058)

  • 1. Meta-analysis of effects of ABCB1 polymorphisms on clopidogrel response among patients with coronary artery disease.
    Zhai Y; He H; Ma X; Xie J; Meng T; Dong Y; Lu J
    Eur J Clin Pharmacol; 2017 Jul; 73(7):843-854. PubMed ID: 28378058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysis.
    Su J; Xu J; Li X; Zhang H; Hu J; Fang R; Chen X
    PLoS One; 2012; 7(10):e46366. PubMed ID: 23056288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the
    Biswas M; Rahaman S; Biswas TK; Ibrahim B
    Expert Opin Drug Saf; 2020 Dec; 19(12):1605-1616. PubMed ID: 33040624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.
    Kim IS; Jeong YH; Park Y; Yoon SE; Kwon TJ; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
    Br J Clin Pharmacol; 2012 Apr; 73(4):629-40. PubMed ID: 22007612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP2C19*2/ABCB1-C3435T polymorphism and risk of cardiovascular events in coronary artery disease patients on clopidogrel: is clinical testing helpful?
    Singh M; Shah T; Adigopula S; Molnar J; Ahmed A; Khosla S; Arora R
    Indian Heart J; 2012; 64(4):341-52. PubMed ID: 22929815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention.
    Tang XF; Wang J; Zhang JH; Meng XM; Xu B; Qiao SB; Wu YJ; Chen J; Wu Y; Chen JL; Gao RL; Yuan JQ; Yang YJ
    Eur J Clin Pharmacol; 2013 May; 69(5):1103-12. PubMed ID: 23150151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome].
    Zhou CF; Ren YH; Song YQ; Yi J; Han BS; Xue Q; Fu ZH; Li DY
    Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Apr; 44(4):309-14. PubMed ID: 27112608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.
    Mega JL; Close SL; Wiviott SD; Shen L; Walker JR; Simon T; Antman EM; Braunwald E; Sabatine MS
    Lancet; 2010 Oct; 376(9749):1312-9. PubMed ID: 20801494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No association of ABCB1 C3435T genotype with clopidogrel response or risk of stent thrombosis in patients undergoing coronary stenting.
    Jaitner J; Morath T; Byrne RA; Braun S; Gebhard D; Bernlochner I; Schulz S; Mehilli J; Schömig A; Koch W; Kastrati A; Sibbing D
    Circ Cardiovasc Interv; 2012 Feb; 5(1):82-8, S1-2. PubMed ID: 22298798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients.
    Zhang L; Chen Y; Jin Y; Qu F; Li J; Ma C; Yang J; Xu B; Wang H; Li X; Li Y; Zhang Y; Lu C; Yin T
    Thromb Res; 2013 Jul; 132(1):81-7. PubMed ID: 23726091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABCB1 C3435T polymorphism and risk of adverse clinical events in clopidogrel treated patients: a meta-analysis.
    Luo M; Li J; Xu X; Sun X; Sheng W
    Thromb Res; 2012 Jun; 129(6):754-9. PubMed ID: 22209339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPLD1 rs12115090 polymorphisms alters antiplatelet potency of clopidogrel in coronary artery disease patients in Chinese Han.
    Wang JY; Zhang YJ; Li H; Hu XL; Li MP; Song PY; Ma QL; Peng LM; Chen XP
    Gene; 2018 Dec; 678():226-232. PubMed ID: 30096456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association between abcb1 gene polymorphism and clopidogrel response variability in stroke ischemic: a cross sectional study.
    Hidayat R; Nabilah RA; Fisher M; Aninditha T; Kurniawan M; Estiasari R; Indrawati LA; Safri AY; Mesiano T; Rasyid A; Harris S
    BMC Neurol; 2024 Jun; 24(1):216. PubMed ID: 38914966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation.
    Liang ZY; Han YL; Zhang XL; Li Y; Yan CH; Kang J
    EuroIntervention; 2013 Jul; 9(3):316-27. PubMed ID: 23872648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variability of platelet response to clopidogrel is not related to adverse cardiovascular events in patients with stable coronary artery disease undergoing percutaneous coronary intervention.
    Olędzki S; Kornacewicz-Jach Z; Safranow K; Kiedrowicz R; Gawrońska-Szklarz B; Jastrzębska M; Gorący J
    Eur J Clin Pharmacol; 2017 Sep; 73(9):1085-1094. PubMed ID: 28589365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
    Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC;
    Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C3435T polymorphism of the ABCB1 gene is associated with poor clopidogrel responsiveness in a Mexican population undergoing percutaneous coronary intervention.
    Calderón-Cruz B; Rodríguez-Galván K; Manzo-Francisco LA; Vargas-Alarcón G; Fragoso JM; Peña-Duque MA; Reyes-Gómez CA; Martínez-Ríos MA; De la Peña-Díaz A
    Thromb Res; 2015 Nov; 136(5):894-8. PubMed ID: 26362473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between P2RY12 gene polymorphisms and adverse clinical events in coronary artery disease patients treated with clopidogrel: A systematic review and meta-analysis.
    Li JL; Fu Y; Qin SB; Liang GK; Liu J; Nie XY; Chen J; Shi LW; Shao H; Lu Y
    Gene; 2018 May; 657():69-80. PubMed ID: 29510176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of CES1A2 A(-816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease.
    Xie C; Ding X; Gao J; Wang H; Hang Y; Zhang H; Zhang J; Jiang B; Miao L
    Pharmacogenet Genomics; 2014 Apr; 24(4):204-10. PubMed ID: 24535487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of genetic and coexisting polymorphisms on platelet response to clopidogrel in Chinese Han patients with acute coronary syndrome.
    Liu X; Luo Y; Lai Y; Yao Y; Li J; Wang Y; Zheng SL; Xu J; Liu X
    J Genet; 2016 Jun; 95(2):231-7. PubMed ID: 27350664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.